Biocryst Pharmaceuticals Stock Market Value
| BCRX Stock | USD 7.71 0.01 0.13% |
| Symbol | BioCryst |
BioCryst Pharmaceuticals Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.61) | Revenue Per Share 2.01 | Quarterly Revenue Growth 0.35 | Return On Assets (0.04) | Return On Equity (19.25) |
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BioCryst Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BioCryst Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BioCryst Pharmaceuticals.
| 11/29/2024 |
| 12/29/2024 |
If you would invest 0.00 in BioCryst Pharmaceuticals on November 29, 2024 and sell it all today you would earn a total of 0.00 from holding BioCryst Pharmaceuticals or generate 0.0% return on investment in BioCryst Pharmaceuticals over 30 days. BioCryst Pharmaceuticals is related to or competes with TG Therapeutics, Axsome Therapeutics, Seres Therapeutics, Madrigal Pharmaceuticals, Kezar Life, Immunic, and Atara Biotherapeutics. BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines More
BioCryst Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BioCryst Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BioCryst Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.63 | |||
| Information Ratio | 0.0161 | |||
| Maximum Drawdown | 18.53 | |||
| Value At Risk | (4.34) | |||
| Potential Upside | 5.27 |
BioCryst Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioCryst Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BioCryst Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use BioCryst Pharmaceuticals historical prices to predict the future BioCryst Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.0283 | |||
| Jensen Alpha | 0.1004 | |||
| Total Risk Alpha | (0.02) | |||
| Sortino Ratio | 0.0144 | |||
| Treynor Ratio | (0.06) |
BioCryst Pharmaceuticals Backtested Returns
At this stage we consider BioCryst Stock to be somewhat reliable. BioCryst Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.0232, which signifies that the company had a 0.0232% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for BioCryst Pharmaceuticals, which you can use to evaluate the volatility of the firm. Please confirm BioCryst Pharmaceuticals' Risk Adjusted Performance of 0.0283, mean deviation of 2.32, and Downside Deviation of 3.63 to double-check if the risk estimate we provide is consistent with the expected return of 0.0767%. BioCryst Pharmaceuticals has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -1.17, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning BioCryst Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, BioCryst Pharmaceuticals is expected to outperform it. BioCryst Pharmaceuticals right now shows a risk of 3.3%. Please confirm BioCryst Pharmaceuticals maximum drawdown, as well as the relationship between the skewness and day typical price , to decide if BioCryst Pharmaceuticals will be following its price patterns.
Auto-correlation | 0.80 |
Very good predictability
BioCryst Pharmaceuticals has very good predictability. Overlapping area represents the amount of predictability between BioCryst Pharmaceuticals time series from 29th of November 2024 to 14th of December 2024 and 14th of December 2024 to 29th of December 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BioCryst Pharmaceuticals price movement. The serial correlation of 0.8 indicates that around 80.0% of current BioCryst Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.8 | |
| Spearman Rank Test | 0.62 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
BioCryst Pharmaceuticals lagged returns against current returns
Autocorrelation, which is BioCryst Pharmaceuticals stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting BioCryst Pharmaceuticals' stock expected returns. We can calculate the autocorrelation of BioCryst Pharmaceuticals returns to help us make a trade decision. For example, suppose you find that BioCryst Pharmaceuticals has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
BioCryst Pharmaceuticals regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If BioCryst Pharmaceuticals stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if BioCryst Pharmaceuticals stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in BioCryst Pharmaceuticals stock over time.
Current vs Lagged Prices |
| Timeline |
BioCryst Pharmaceuticals Lagged Returns
When evaluating BioCryst Pharmaceuticals' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of BioCryst Pharmaceuticals stock have on its future price. BioCryst Pharmaceuticals autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, BioCryst Pharmaceuticals autocorrelation shows the relationship between BioCryst Pharmaceuticals stock current value and its past values and can show if there is a momentum factor associated with investing in BioCryst Pharmaceuticals.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.